Printer Friendly

SciClone Announces ZADAXIN Poster to Be Presented At AASLD.

Business Editors/Health/Medical Writers


SAN MATEO, Calif.--(BUSINESS WIRE)--Oct. 2, 2003

SciClone Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced the following poster presentation on ZADAXIN(R) (thymosin alpha 1, thymalfasin) at The American Association for the Study of Liver Diseases (AASLD) meeting in Boston:

A pilot trial of thymalfasin (thymosin alpha 1) in combination with PEGinterferon alpha-2a (PEG-IFN2a) and ribavirin in HCV non-responders: 12-week interim results (abstract #228); Saturday, October 25, 5:30 p.m. - 8:00 p.m. The authors of the abstract are: Jorge L. Poo, Xochitl Garcia, Eduardo B. Martins, and David Kershenobich.

For further information about this conference, please visit


ZADAXIN is a pure synthetic preparation of thymosin alpha 1, a substance which circulates in the blood naturally and is instrumental in the body's immune response to fight viral infections and certain cancers. ZADAXIN is easily and safely administered just under the skin twice a week. After administration, thymosin alpha 1 circulates at 50 to 100 times its normal level in the body.

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone is currently evaluating its lead product ZADAXIN in several late stage clinical trials, including two phase 3 hepatitis C clinical trials in the U.S., a recently completed phase 3 hepatitis B clinical trial in Japan, a phase 2 malignant melanoma clinical trial in Europe, and two phase 2 liver cancer pilot studies in the U.S. Other drug development candidates include SCV-07, a potentially orally available therapeutic to treat viral and infectious diseases, and other products to treat cystic fibrosis. For more information about SciClone, visit
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Oct 2, 2003
Previous Article:USF Holland Receives Carrier Award; Miller Electric Cites Consistent Performance.
Next Article:Diodes Incorporated Upgraded to ISO 9001:2000 Standards.

Related Articles
ZADAXIN Adds Benefit to Pegylated Interferon for HCV Non-Responders; Hepatitis C Patients Who Failed Prior Therapy Responding to ZADAXIN.
SciClone Pharmaceuticals Reports Third Quarter 2002 Results; New Data Support Clinical Trials; ZADAXIN Sales up 20%.
SciClone's ZADAXIN in Triple Therapy Shows 61% Early Virologic Response for Hepatitis C Non-Responders; 12-Week Data Presented at World's Largest...
SciClone Reports Third Quarter Results; Sales of ZADAXIN Increase 26% to $5.4 Million.
AIDS treatment and related conference calendar (Starting September 2004).
SciClone Announces ZADAXIN Poster to Be Presented at AASLD.
SciClone's ZADAXIN Shows Promise in Triple Therapy Trial for Hepatitis C Non-Responder Patients; Endpoint Data Presented at World's Largest Meeting...
The hepatitis C drug development pipeline.
The Mississippi Junior Academy of Science.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters